Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-CD7 UCAR-T cells for CD7+ T/NK cell malignancies
NCT04264078Phase 1Unknown
- Sponsor
- Xinqiao Hospital
- Start
- Mar 2021
- Primary completion
- Jun 2022
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GC027F in t-cell acute lymphoblastic leukemia (T-ALL), T-cell acute lymphoblastic lymphoma (T-LBL), T-cell non-Hodgkin lymphoma and 1 more, sponsored by Xinqiao Hospital. Primary endpoint: Overall Response Rate at 4 weeks. Status: unknown.
02
Drugs
GC027F
03
Conditions
t-cell acute lymphoblastic leukemia (T-ALL)T-cell acute lymphoblastic lymphoma (T-LBL)T-cell non-Hodgkin lymphomanatural killer cell lymphoma (NKCL)
Beyond the preview
Go deeper on NCT04264078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04264078.